NCT04728035
Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance treatment 1 completed NCT02599363
A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer treatment 1 completed NCT03474822
Plasmodium Immunotherapy for Breast and Liver Cancers No drug interventions treatment 1 / 2 recruiting NCT03282825
Clinical Study of Decitabine and Paclitaxel Combination Therapy treatment 1 unknown_status NCT00754325
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor treatment 2 completed NCT05861830
Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES) treatment 3 recruiting NCT00305448
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg treatment 2 completed NCT00322348
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women treatment 2 completed NCT02580448
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) treatment 1 / 2 completed NCT03071926
Metronomic PLD in Patients With Primary Endocrine Resistant ABC treatment 2 unknown_status NCT05812326
PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer No drug interventions treatment 1 / 2 completed NCT00496366
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer treatment 2 terminated NCT05876065
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer treatment Not Available recruiting NCT05753865
A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound) treatment 3 not_yet_recruiting NCT00428220
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. treatment Not Available completed NCT04655573
A Pilot Study of a Micro-Organosphere Drug Screen Platform to Lead Care in Advanced Breast Cancer No drug interventions Not Available Not Available terminated NCT03850873
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics No drug interventions treatment 1 unknown_status NCT04227327
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) treatment 2 active_not_recruiting NCT02091960
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer treatment 2 completed NCT06107894
TIL Therapy for Patients With Advanced Solid Tumors treatment 1 not_yet_recruiting NCT03025880
Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC treatment 2 completed NCT03047889
A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast No drug interventions Not Available Not Available unknown_status NCT06157892
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors treatment 1 / 2 recruiting NCT03072992
"Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer treatment 2 completed NCT01836640
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer No drug interventions Not Available Not Available terminated NCT00452140
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment treatment 2 terminated NCT04653740
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer No drug interventions other Not Available unknown_status NCT00398567
A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer treatment 1 / 2 completed NCT00546104
Phase II Dasatinib Study in Advanced Breast Cancer treatment 2 completed NCT05191004
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC treatment 1 / 2 withdrawn NCT06470672
Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer treatment 2 not_yet_recruiting NCT05424068
Rehabilitation for People With Advanced Cancer No drug interventions supportive_care Not Available recruiting NCT03285568
Patterns of Prescribing and Monitoring of Palbociclib Not Available Not Available completed NCT00327769
Faslodex Advanced Breast Cancer Local Chinese Study treatment 3 completed NCT04316169
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer treatment 1 withdrawn NCT02499146
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer other 1 unknown_status NCT03245112
Halaven Patient Registry (Metastatic Breast Cancer, MBC) Not Available Not Available unknown_status NCT04004910
A Study Comparing Immunopheresis® Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Treatment of Advanced Breast Cancer Patients No drug interventions treatment 1 / 2 unknown_status NCT05438810
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. treatment 3 unknown_status NCT06339281
A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer treatment 2 not_yet_recruiting NCT05933395
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor treatment 2 recruiting NCT06354114
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 No drug interventions treatment 2 not_yet_recruiting NCT05323955
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib treatment 2 recruiting NCT05654623
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. treatment 3 recruiting NCT05255523
Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer prevention 2 not_yet_recruiting NCT06044623
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients No drug interventions treatment 3 recruiting NCT04920708
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression treatment 2 recruiting NCT01876238
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer No drug interventions supportive_care Not Available completed NCT03312738
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor treatment 2 completed NCT06301438
Dalpiciclib in HR+/HER2- ABC Not Available Not Available not_yet_recruiting NCT04862143
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant treatment 2 terminated NCT05085002
A Study of Lerociclib in Participants With Advanced Breast Cancer treatment 2 terminated NCT06047184
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer treatment 1 active_not_recruiting NCT04524000
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer treatment 2 active_not_recruiting NCT04188548
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer treatment 1 active_not_recruiting NCT04222413
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT05274451
A Study to Investigate LYL797 in Adults with Solid Tumors No drug interventions treatment 1 recruiting NCT06176534
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial treatment 2 recruiting NCT06380751
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer treatment 3 recruiting NCT06555588
Engage Psychosocial Intervention for Cancer Symptoms No drug interventions supportive_care Not Available not_yet_recruiting NCT06548919
Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer Not Available Not Available recruiting NCT06544577
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC Not Available Not Available recruiting NCT06525675
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) Not Available Not Available active_not_recruiting NCT06016738
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer treatment 3 recruiting NCT06123988
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer No drug interventions supportive_care Not Available not_yet_recruiting NCT03577197
Southeast Netherlands Advanced Metastatic Breast Cancer Registry No drug interventions Not Available Not Available recruiting NCT06500494
To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment Not Available Not Available not_yet_recruiting NCT06507930
The COMPASSION Study No drug interventions health_services_research Not Available not_yet_recruiting NCT06120283
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors treatment 1 recruiting NCT05810870
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin treatment 2 recruiting NCT06263543
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC treatment 2 recruiting NCT06382948
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. treatment 3 not_yet_recruiting NCT06486883
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype treatment 2 not_yet_recruiting NCT03205761
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer treatment 2 completed NCT04408118
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC treatment 2 completed NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer treatment 1 recruiting NCT06447623
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer treatment 3 recruiting NCT04482244
RCT of CBD for Anxiety in Advanced Breast Cancer treatment 2 active_not_recruiting NCT05077449
A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer treatment 3 active_not_recruiting NCT06433609
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer treatment 2 not_yet_recruiting NCT05893368
New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer No drug interventions Not Available Not Available recruiting NCT05142475
Study on TIL for the Treatment of Advanced Breast Cancer No drug interventions treatment 0 recruiting NCT06125834
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy treatment 2 recruiting NCT06375707
Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer treatment 2 recruiting NCT05063786
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) treatment 3 active_not_recruiting NCT06298084
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd treatment 1 / 2 recruiting NCT06328387
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer treatment 1 / 2 recruiting NCT06338605
Evaluating the Incidence of Pseudo-Acute Kidney Injuries in Patients With Metastatic Breast Cancer on CDK4/6 Inhibitors Trough Cystatin C Analysis No drug interventions Not Available Not Available active_not_recruiting NCT05631795
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment treatment 4 recruiting NCT05383170
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers treatment 1 / 2 active_not_recruiting NCT06217185
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). treatment 4 recruiting NCT06290466
Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects No drug interventions treatment 1 completed NCT05759949
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors treatment 1 active_not_recruiting NCT05949541
Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer treatment 2 recruiting NCT05594095
SNF Platform Study of HR+/ HER2-advanced Breast Cancer treatment 2 recruiting NCT02768337
Cambridge Brain Mets Trial 1 other 1 / 2 terminated NCT03878823
Safety and Pharmacokinetics of ODM-209 No drug interventions treatment 1 / 2 completed NCT05508906
Phase 1b Combo w/ Ribociclib and Alpelisib treatment 1 recruiting NCT06102824
Organoid-based Functional Precision Therapy for Advanced Breast Cancer treatment 2 recruiting NCT05173103
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer No drug interventions Not Available Not Available recruiting NCT06193525
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test treatment 2 recruiting NCT03052634
A Study of RC48-ADC in Subjects With Advanced Breast Cancer No drug interventions treatment 1 / 2 completed NCT03669497
Hypo-Fractionated Radiotherapy in Breast Cancer No drug interventions treatment Not Available completed NCT04714619
CB-103 Plus NSAI In Luminal Advanced Breast Cancer treatment 2 terminated NCT02422615
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. treatment 3 completed NCT03481998
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer treatment 1 / 2 completed NCT03685331
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer treatment 1 active_not_recruiting NCT06098599
Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer treatment 1 completed NCT05655598
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer treatment 1 recruiting NCT03809988
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) treatment 2 completed NCT04420598
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease treatment 2 completed NCT03280303
Palbociclib in Real World Practice No drug interventions Not Available Not Available completed NCT04541225
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors No drug interventions treatment 1 terminated NCT04304352
Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients treatment 2 recruiting NCT04756765
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer treatment 2 recruiting NCT04942054
A Study in Patients With Advanced Breast Cancer No drug interventions treatment 1 terminated NCT05831878
RC48-ADC in HER2-low Advanced Breast Cancer treatment Not Available recruiting NCT04097756
A Phase I Study of LX-039 Tablets No drug interventions treatment 1 completed NCT05452213
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients treatment 4 recruiting NCT04733417
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. treatment 2 active_not_recruiting NCT02027376
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients treatment 1 completed NCT04826016
POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer treatment 1 / 2 withdrawn NCT04953377
PFMT Educational Intervention for Patients With Advancer Breast Cancer No drug interventions treatment Not Available recruiting NCT05076591
IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors No drug interventions treatment 1 recruiting NCT05775575
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer No drug interventions treatment 1 / 2 recruiting NCT04924699
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer treatment 2 / 3 recruiting NCT02401347
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors treatment 2 completed NCT03931551
Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer treatment 2 terminated NCT03829306
Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA) No drug interventions Not Available Not Available completed NCT05536128
Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor treatment 2 not_yet_recruiting NCT05530057
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer treatment 2 recruiting NCT05469750
Dalpiciclib Plus Letrozole and Capecitabine treatment 2 not_yet_recruiting NCT05439499
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer. treatment 3 recruiting NCT05431504
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis treatment 2 not_yet_recruiting NCT05337657
A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer treatment 1 recruiting NCT05274893
A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer other 1 not_yet_recruiting NCT05257395
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer treatment 3 not_yet_recruiting NCT05227131
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer treatment 2 withdrawn NCT05156619
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap No drug interventions Not Available Not Available recruiting NCT05047848
Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer treatment Not Available recruiting NCT05020964
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib treatment 2 not_yet_recruiting NCT04892693
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency treatment 2 recruiting NCT04856371
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer treatment 1 not_yet_recruiting NCT04539496
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors No drug interventions treatment 1 / 2 recruiting NCT04456855
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients No drug interventions Not Available Not Available unknown_status NCT04436393
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer No drug interventions Not Available Not Available completed NCT04030728
Implementing Patients´ Competence in Oral Breast Cancer Therapy No drug interventions Not Available Not Available unknown_status NCT03966898
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer treatment 3 active_not_recruiting NCT03927456
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer treatment 3 active_not_recruiting NCT03811418
A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer other 3 withdrawn NCT03538171
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer treatment 3 active_not_recruiting NCT03524261
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer No drug interventions treatment 2 withdrawn NCT03455270
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer treatment 1 completed NCT03405168
Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer treatment 2 completed NCT03240224
Bioinformation Therapy for Breast Cancer No drug interventions treatment 2 / 3 completed NCT03182634
The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial other 2 recruiting NCT03125746
A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors treatment 1 unknown_status NCT02952729
Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 No drug interventions treatment 1 completed NCT02657889
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer treatment 1 / 2 completed NCT02069093
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer prevention 2 completed NCT02054338
A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer treatment 3 terminated NCT01989546
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations treatment 1 / 2 completed NCT01976169
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) treatment 1 completed NCT01931943
A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer No drug interventions treatment 1 unknown_status NCT01311037
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer No drug interventions Not Available Not Available unknown_status NCT00915369
A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer treatment 1 unknown_status NCT00874146
Level of HER2-neu Gene Amplification an Response to Trastuzumab No drug interventions Not Available Not Available unknown_status NCT00793546
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer treatment 2 terminated NCT00777101
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer treatment 2 completed NCT00719875
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer treatment 1 completed NCT00717951
A Randomised,Multi-Center Study of Docetaxol Plus Capecitabine or Cisplatin in Anthracycline-Pretreated Patients With Advanced Breast Cancer treatment 2 unknown_status NCT00635713
Second Line Breast Cancer Trial treatment 3 completed NCT00562458
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer Not Available Not Available completed NCT00561119
Maintenance Versus Observation After 6 Cycles of Gemcitabine Plus Paclitaxel in Pts With Advanced Breast Cancer treatment 3 completed NCT00522457
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy treatment 2 terminated NCT00494481
E3 Breast Cancer Taxotere Combination treatment 2 completed NCT00454805
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer. treatment 2 completed NCT00452673
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer treatment 1 completed NCT00445458
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer treatment 1 / 2 completed NCT00387907
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer treatment 2 completed NCT00328120
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients treatment 1 completed NCT00313170
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg treatment 2 completed NCT00106145
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014) treatment 1 completed